Ludwig Enterprises Inc, operates as a biotech and healthcare holding company. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2007-12-11. The firm is engaged in mRNA genomics and machine learning artificial intelligence (AI) technology. AI technology is used to extrapolate inflammatory signals that are correlated to different types of cancer and chronic diseases. The company developed an early screening cancer diagnostic kit, Revealia, utilizing a mail-order cheek swab that is sold directly to consumers. The proprietary test is patent-pending and contains multi-cancer early detection screening technology in a painless convenient solution that is accurate compared to alternative early screening test kits. The core research driving the diagnostic business opportunities comes from the ongoing identification and monitoring of patients that present varying degrees of chronic inflammation which is the causative agent of illnesses, such as cancer and heart disease. The company also holds the intellectual property and patent of the mRNA Neuro Panel and Serotonin Assay.
